Isabelle Riviere
Directeur/Bestuurslid bij Centre For Commercialization of Cancer Immunotherapy
Profiel
Isabelle Riviere is the founder of Juno Therapeutics, Inc. which was founded in 2013.
Currently, she holds the position of Director at the Centre For Commercialization of Cancer Immunotherapy.
Actieve functies van Isabelle Riviere
| Bedrijven | Functie | Begin |
|---|---|---|
Centre For Commercialization of Cancer Immunotherapy
 Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Isabelle Riviere
| Bedrijven | Functie | Einde |
|---|---|---|
| JUNO THERAPEUTICS INC | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. |
